Erlotinib

Generic Name: Erlotinib

Brand Names: Tarceva

Drug Type: Small Molecule

Chemical Formula: C_₂₂H_₂₃N_₃O_₄

CAS Number: 183321-74-6

Unique Ingredient Identifier: J4T82NDH7E

Background: Erlotinib is an inhibitor of the epidermal growth factor receptor (EGFR) tyrosine kinase that is used in the treatment of non-small cell lung cancer, pancreatic cancer and several other types of cancer. It is typically marketed under the trade name Tarceva. Erlotinib binds to the epidermal growth factor receptor (EGFR) tyrosine kinase in a reversible fashion at the adenosine triphosphate (ATP) binding site of the receptor. Recent studies demonstrate that erlotinib is also a potent inhibitor of JAK2V617F, which is a mutant form of tyrosine kinase JAK2 found in most patients with polycythemia vera (PV) and a substantial proportion of patients with idiopathic myelofibrosis or essential thrombocythemia. This finding introduces the potential use of erlotinib in the treatment of JAK2V617F-positive PV and other myeloproliferative disorders.

Indication: Erlotinib is indicated for:

The safety and efficacy of erlotinib have not been established for patients with NSCLC whose tumors show other EGFR mutations. Additionally it is not recommended for use in combination with platinum-based chemotherapy.

Associated Conditions: Locally Advanced Pancreatic Cancer (LAPC), Metastatic Non-Small Cell Lung Cancer, Pancreatic Metastatic Cancer, Unresectable Pancreatic Cancer

Associated Therapies: -

Clinical Trials

Gemcitabine Plus Erlotinib in RASH-positive Patients With Metastatic Pancreatic Cancer

Phase 2

Conditions: Metastatic Pancreatic Adenocarcinoma

Interventions: Drug: Gemcitabine
Drug: Oxaliplatin
Drug: Erlotinib
Drug: Folinic Acid
Drug: Irinotecan
Drug: 5-FU

First Posted Date: 2012-11-20

Last Posted Date: 2017-07-19

Lead Sponsor: Ludwig-Maximilians - University of Munich

Target Recruit Count: 150

Registration Number: NCT01729481

Locations: 🇩🇪
University of Munich, Munich, Germany

A Phase I/II Study of Tivozanib and Erlotinib as Initial Treatment for Metastatic Non-small Cell Lung Cancer Assigned by VeriStrat® Serum Proteomic Evaluation

Phase 1

Withdrawn

Conditions: Non-small Cell Lung Cancer
Stage IV Disease
EGFR Unknown or Wild-type

Interventions: Drug: Erlotinib
Drug: Tivozanib
Other: Standard of Care treatment

First Posted Date: 2012-11-16

Last Posted Date: 2013-07-25

Lead Sponsor: University of Utah

Registration Number: NCT01728181

Study of REGN1400 Alone and in Combination With Erlotinib or Cetuximab in Patients With Certain Types of Cancer

Phase 1

Completed

Conditions: Cancer

Interventions: Drug: REGN1400
Drug: Erlotinib
Drug: Cetuximab

First Posted Date: 2012-11-16

Last Posted Date: 2015-04-06

Lead Sponsor: Regeneron Pharmaceuticals

Target Recruit Count: 56

Registration Number: NCT01727869

Erlotinib in Post Radical Operation NSCLC Patients With EGFR Mutation

Phase 2

Conditions: Non-small Cell Lung Cancer Stage III

Interventions: Drug: cis-platinum
Drug: Erlotinib
Drug: Vinorelbine

First Posted Date: 2012-09-11

Last Posted Date: 2016-10-20

Lead Sponsor: Tianjin Medical University Cancer Institute and Hospital

Target Recruit Count: 94

Registration Number: NCT01683175

Locations: 🇨🇳
The affiliated hospital of medical college Qingdao University, Qingdao, China
🇨🇳
Zhejiang Cancer Hospital, Hangzhou, China
🇨🇳
The third affiliated hospital of Harbin Medical Univer, Harbin, China

and more 12 locations

A Study of Erlotinib in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Phase 3

Completed

Conditions: Non-Small Cell Lung Cancer

Interventions: Drug: Erlotinib

First Posted Date: 2012-08-17

Last Posted Date: 2019-12-20

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 375

Registration Number: NCT01667562

Locations: 🇷🇸
Clinical Center Nis; Clinic for pulmonary diseases Knez Selo, Nis, Serbia
🇷🇸
Clinical Center Bezanijska Kosa; Oncology, Belgrade, Serbia
🇷🇸
Clinic for Pulmonology, Clinical Center of Serbia, Belgrade, Serbia

and more 1 locations